Precipio, Inc. (PRPO) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Precipio, Inc. is a healthcare biotechnology company focused on cancer diagnostics, operating CLIA-certified laboratories in New Haven, Connecticut, and Omaha, Nebraska. The company develops diagnostic products and services to address cancer misdiagnoses. This report covers the quarterly period ended September 30, 2024.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Net Sales | $5.21 million | $4.52 million | $13.08 million | $10.87 million |
| Gross Profit | $2.28 million | $1.89 million | $4.91 million | $4.01 million |
| Gross Margin | 44% | 42% | 38% | 37% |
| Operating Loss | $(0.60) million | $(1.45) million | $(3.88) million | $(6.77) million |
| Net Loss | $(0.63) million | $(1.46) million | $(3.93) million | $(6.78) million |
| Loss Per Share (Diluted) | $(0.42) | $(1.04) | $(2.69) | $(5.39) |
| Cash and Equivalents | $1.05 million (as of Sept 30, 2024) | |||
| Working Capital | $(1.22) million deficit (as of Sept 30, 2024) | |||
| Accumulated Deficit | $(102.1) million (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15% in Q3 and 20% YTD compared to the prior year. This was driven by a significant increase in diagnostic testing case volume (70% increase in Q3; 78% increase YTD), partially offset by a lower average price per case due to product mix changes.
- Expense Reduction: Operating expenses decreased by $0.5 million in Q3 and $2.0 million YTD. Reductions were primarily due to lower personnel costs in sales and marketing and research and development.
- Improved Cash Flow: Net cash used in operating activities improved significantly to $(0.13) million for the nine months ended Sept 30, 2024, compared to $(3.67) million in the prior year period.
- Debt Activity: The company entered into a new $250,000 business loan agreement in May 2024 with a 20% interest rate. Total long-term debt (net of current maturities) stands at $0.53 million.
Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern for the next twelve months. This is due to recurring losses, a working capital deficit, and the need for additional financing to meet debt obligations.
- Change Healthcare Cyberattack: A cyberattack on billing vendor Change Healthcare in February 2024 caused significant billing delays. The company received approximately $1.1 million in temporary funding assistance from Change Healthcare, which is now due for repayment starting January 2, 2025. The company anticipates negotiating a repayment plan.
- Capital Resources: The company has approximately $3.7 million remaining availability under its "At-The-Market" (ATM) sales agreement with AGP to raise additional capital.
- Regulatory Risks: The FDA has issued a final rule to end enforcement discretion for Laboratory Developed Tests (LDTs) in phases starting May 2025, which may require costly compliance measures. Additionally, the company faces potential legal action from vendors regarding delinquent accounts payable.
- Stock Option Repricing: In August 2024, the company repriced approximately 177,000 stock options, reducing the exercise price to $6.56. This resulted in an incremental compensation cost of approximately $0.5 million to be recognized over 1.4 years.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $1.05 million cash balance against the $1.22 million working capital deficit and upcoming debt repayments.
- Change Healthcare Repayment: Monitor the status of negotiations for the $1.1 million repayment to Change Healthcare due in January 2025.
- ATM Utilization: Track the execution of the remaining $3.7 million ATM offering to assess the ability to fund operations without further dilution.
- Regulatory Compliance: Assess the financial impact of the new FDA LDT regulations effective May 2025 on the company's core testing services.
- Vendor Relations: Review the status of delinquent accounts payable and potential legal actions from suppliers.